News Release

Toxicology validation study underway in Canada

Date: August 16, 2000

CDNX Trading Symbol: WXI
World Wide Web: http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. ( the "company") is pleased to announce that it is continuing the laboratory program of validating the Chinese lab results in Canada. The acute and subacute toxicity stage has now commenced.

The company can announce that the initial indications for the acute validations in Canada on rats show very similar results to the Chinese tests. This is positive for the company.

Every substance (ie. chemical), including distilled water, has toxicity with the potential to harm the body. The dividing line is the amount of product consumed at any one time or over a period of time. For most products a low dose would create no reaction but at higher levels or more frequent dosing a response would be expected. Testing on humans can be extremely dangerous and thus rats and/or mice are usually used at this stage and these are referred to as acute and subacute tests.

 Acute is a very simple test. Doses are given at various levels until 50% of the animals succumb. The different levels of doses in relation to mortality are noted and the resulting graph equals the LD50. This value, because it is valued in relationship to the dose vis-a-vis the weight of the animal, can be extrapolated for humans.

In the subacute studies, doses of significantly less strength then the LD50 indicated are used. This test is primarily concerned with the potential adverse effect(s) that the substance can do to the human organs. Animals who have received doses over a period of time, some up to 28 days or more, are tested for various other analysis to determine deleterious effects on the body by continual usage of said substance.

This now successfully completes 3 of the 7 validation tests contracted for with Canadian laboratories. In all cases the laboratories, when doing their testing, are completing these tests according to the standards for the HPB (Canada), FDA (USA), EMEA (Europe) and ICH (International Conference on Harmonization).

Tetrodin(HT) has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin(HT) as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.